Precision Biosensor

Precision Biosensor Capital Expenditures

The Capital Expenditures (CapEx) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is -157.43 M KRW. In the previous year, Capital Expenditures (CapEx) was -64.96 M KRW — a change of 142.36% (lower).

Capital Expenditures

-157.43 MKRW

YoY

142.36%

Last updated:

Capital Expenditures (CapEx) of Precision Biosensor is 2025 -157.43 M KRW. Capital Expenditures (CapEx) of Precision Biosensor was 2024 -64.96 M KRW. It decreases by 142.36% lower compared to the previous year.

The Precision Biosensor Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-404.96 M KRW
Jan 1, 2019
-216.43 M KRW
Jan 1, 2020
-2.11 B KRW
Jan 1, 2021
-9.15 B KRW
Jan 1, 2022
-11.14 B KRW
Jan 1, 2023
-7.05 B KRW
Jan 1, 2024
-64.96 M KRW
Jan 1, 2025
-157.43 M KRW
The Precision Biosensor Capital Expenditures history
YEARCapital ExpendituresYoY
-157.43 MKRW+142.36%
-64.96 MKRW-99.08%
-7.05 BKRW-36.70%
-11.14 BKRW+21.76%
-9.15 BKRW+333.66%
-2.11 BKRW+875.04%
-216.43 MKRW-46.56%
-404.96 MKRW-22.25%
-520.84 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Capital Expenditures (CapEx) of Precision Biosensor is -157.43 M KRW in 2025.

Capital Expenditures (CapEx) of Precision Biosensor changed from -64.96 M KRW to -157.43 M KRW, representing a 142.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Precision Biosensor historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Precision Biosensor

All Key Metrics — Precision Biosensor